马来西亚癌症临终关怀质量指标的利益相关者共识:一项改良德尔菲研究
该研究旨在编制一套由专家认可的、用于评估马来西亚癌症患者临终关怀质量的质量指标(QIs)。研究者首先通过范围综述识别候选QIs,然后进行五轮在线改良德尔菲调查,由肿瘤学和姑息治疗医护人员、照护者和患者倡导者组成的专家小组对每个QIs的相关性进行9分制评分,医护人员还评估了从病历中提取这些指标的可行性。QIs需满足中位评分≥7且≥75%的评分≥7才被视为认可。47名受邀专家中39名参与(应答率83.0%),包括31名医护人员、5名照护者和3名患者倡导者。从初始64项指标中,最终认可了31项指标,涵盖10个领域。结论认为这套全面的31项指标可用于评估癌症患者接受的临终关怀质量,并作为未来质量改进举措的基础;需要进一步研究在真实临床实践中验证这些QIs,并评估从病历中提取这些指标的可行性和可靠性。
要点
- 改良德尔菲研究最终认可31项癌症临终关怀质量指标,覆盖10个领域,来自初始64项指标。
- 认可标准为:中位评分≥7且≥75%的评分≥7。
- 症状管理领域指标最多,共11项(如疼痛、呼吸困难、谵妄和躁动评估)。
- 未获认可的指标包括住院领域(如ICU入住)3项和精神关怀领域(如精神需求评估)2项。
- 作者认为这些QIs可用于评估临终关怀质量并作为质量改进的基础,但需进一步研究验证。
适用人群与场景
- 马来西亚的癌症临终关怀患者。
- 专家小组包括肿瘤学和姑息治疗医护人员、照护者和患者倡导者;可行性评估仅由医护人员完成。
诊断标准与关键阈值
- QIs认可标准:中位评分≥7且≥75%的评分≥7(采用9分Likert量表)。
研究设计与关键结果
- 研究类型:改良德尔菲研究(五轮在线调查),先通过范围综述识别候选QIs。
- 样本量:47名专家受邀,39名参与(应答率83.0%),包括31名医护人员、5名照护者和3名患者倡导者。
- 初始64项指标中,31项获得认可,分布在10个领域:症状管理(如疼痛、呼吸困难、其他躯体症状包括谵妄和躁动评估)11项、心理和社会方面(如抑郁评估)2项、治疗方式(如化疗止吐)1项、医院和社区姑息治疗服务(如家庭访视)5项、预立医疗照护计划(如复苏偏好)2项、连续性和协调性照护(如多学科团队会诊)5项、死亡和照护地点(如首选死亡地点)4项、呼吸道分泌物药物1项。
- 未获认可的指标包括住院领域(如重症监护室入住)3项和精神关怀领域(如精神需求评估)2项。
证据类型、等级与局限
- 证据类型:改良德尔菲研究(专家共识)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为这31项QIs可用于评估癌症患者接受的临终关怀质量,并作为未来质量改进举措的基础。
- 作者指出需要进一步研究在真实临床实践中验证这些QIs,并评估从病历中提取这些指标的可行性和可靠性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: End-of-life care is an essential component of cancer care. Good end-of-life care improves quality of life for the dying individuals and their loved ones. This study aimed to compile a list of quality indicators (QIs) endorsed by experts, for assessing the quality of end-of-life care for cancer patients in Malaysia.
METHODS: Eligible QIs were first identified through a scoping review, which formed the basis for a five-round online modified Delphi survey that was undertaken to reach expert panel agreement. Firstly, the relevance of each QI was rated by a panel comprising healthcare professionals (HCPs) in oncology and palliative care, caregivers, and patient advocates using a 9-point Likert scale. Secondly, the feasibility of extracting these indicators from medical charts was evaluated using the same rating scale; this was assessed only by HCPs due to their familiarity with the documentation practices. QIs with a median score ≥ 7 and with ≥ 75% of rating ≥ 7 were considered endorsed.
RESULTS: Of the 47 experts invited, 39 participated (response rate 83.0%): 31 HCPs, five caregivers and three patient advocates. From an initial list of 64 indicators, 31 were endorsed across 10 domains, including measures related to: symptom management such as pain, dyspnoea, and other physical symptoms (e.g., assessment of delirium and agitation) (n = 11/64); psychological and social aspects of care (e.g., depression assessment) (n = 2/64), treatment modalities (e.g., antiemetics for chemotherapy) (n = 1/64); hospital and community palliative care services (e.g., home care visits) (n = 5/64); advanced care planning (e.g., resuscitation preference) (n = 2/64); continuity and coordination of care (e.g., multidisciplinary team consultation) (n = 5/64); place of death and care (e.g., preferred place of death) (n = 4/64); and medications for respiratory secretion (n = 1/64). Some unendorsed indicators included those from the domains of hospitalisation (e.g., intensive care unit admission) (n = 3/64) and spiritual care (e.g., spiritual needs assessment) (n = 2/64).
CONCLUSIONS: A comprehensive set of 31 indicators was identified. These QIs can be used for evaluating the quality of end-of-life care received by cancer patients and serve as a foundation for future quality improvement initiatives. Further studies are needed to validate these QIs in real-world clinical practice and assess the feasibility and reliability of extracting these indicators from medical charts.
参考来源
- Wong WJ, Hwong WY, Teoh CCO, et al. Stakeholder consensus of quality indicators for end-of-life cancer care in Malaysia: a modified Delphi study. BMC Palliat Care. 2025. PMID: 41310558. doi:10.1186/s12904-025-01947-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。